Axin is a negative regulator of canonical Wnt signaling, which promotes the degradation of b-catenin, the major effector in this signaling cascade. While many protein-binding domains of Axin have been identified, their significance has not been evaluated in vivo. Here, we report the generation and analysis of mice carrying modified Axin alleles in which either the RGS domain or the six C-terminal amino acids (C6 motif) were deleted. The RGS domain is required for APC-binding, while the C6 motif has been implicated in the activation of c-Jun N-terminal kinase, but is not required for the effects of Axin on the Wnt/b-catenin pathway, in vitro. Both mutant Axin alleles caused recessive embryonic lethality at E9.5-E10.5, with defects indistinguishable from those caused by a null allele. As Axin-DRGS protein was produced at normal levels, its inability to support embryogenesis confirms the importance of interactions between Axin and APC. In contrast, Axin-DC6 protein was expressed at only 25-30% of the normal level, which may account for the recessive lethality of this allele. Furthermore, many Axin DC6/DC6 embryos that were heterozygous for a b-catenin null mutation survived to term, demonstrating that early lethality was due to failure to negatively regulate b-catenin.
A XIN is a key negative regulator of the canonical Wnt signaling pathway (Zeng et al. 1997) , which functions by promoting the degradation of b-catenin, the major effector in the signaling cascade (Luo and Lin 2004) . The related protein Axin2/Conductin is thought to function similarly (Behrens et al. 1998 ), and appears to have partially overlapping roles in development. Loss of Axin results in early embryonic lethality (Zeng et al. 1997) , while Axin2 null mice are viable but display skull malformations (Yu et al. 2005) . Mutations in both genes are associated with cancer in humans (Salahshor and Woodgett 2005) . The lack of redundancy between Axin and Axin2 is apparently due to their different modes of expression: while Axin is expressed ubiquitously (Zeng et al. 1997) , Axin2 is expressed in a tissue-and developmental stage-specific pattern, and its transcription is induced by canonical Wnt signaling ( Jho et al. 2002; Lustig et al. 2002; Aulehla et al. 2003) . The functional equivalence of Axin and Axin2 in vivo was established by generating knockin mice in which the Axin gene was replaced with an Axin2 cDNA. The mutant mice, which expressed no endogenous Axin, but produced Axin2 under control of the Axin locus, were phenotypically normal (Chia and Costantini 2005) .
Axin has a number of domains that interact with other proteins, many of which are known to be involved in canonical Wnt signaling (e.g., GSK3, b-catenin, Dvl, and LRP5/6), but some of which are not (e.g., MEKK1, MEKK4, Smad3, and I-mfa) (Fagotto et al. 1999; Hsu et al. 1999; Jho et al. 1999; Kishida et al. 1999; Li et al. 1999; Yamamoto et al. 1999; Julius et al. 2000; Mao et al. 2001; Luo and Lin 2004) . While the locations of many protein-binding domains of Axin have been determined, the functional significance of many of these domains is unclear. Most previous structure-function studies of Axin used a gain-of-function approach, in which an altered form of Axin was overexpressed in cell lines or frog embryos, in the presence of endogenous wild-type Axin and assayed for its ability to regulate b-catenin signaling or embryonic axis formation. To test the importance of different domains of Axin under physiological conditions, we have used a knockin approach to generate mutant alleles of the mouse Axin locus, and ask if they could support normal development in vivo. Our strategy was based on the demonstration that replacement of the Axin gene by a Myc-tagged Axin (or Axin2) cDNA, by targeting in embryonic stem (ES) cells, was not only efficient, but produced mice with no apparent abnormalities.
The two domains we examine here are the ''RGS domain'' in the N-terminal region and the KVEKVD motif at the C terminus ( Figure 1A ). The RGS domain of Axin, although named for its sequence similarity to regulators of G-protein signaling, is thought to be important primarily as the binding site for APC (Hart et al. 1998; Ikeda et al. 1998; Julius et al. 2000) . APC is another important regulator of b-catenin levels, and mutations in APC are found in colon tumor cells with high levels of b-catenin and constitutively active TCF/ b-catenin nuclear complexes (Munemitsu et al. 1995) . The addition of exogenous wild-type APC into APC-null colon carcinoma cells reduces b-catenin levels, and antagonizes TCF/b-catenin-mediated transcription, demonstrating that APC negatively regulates b-catenin levels (Korinek et al. 1997) . Surprisingly, it was reported that Axin is capable of degrading b-catenin when overexpressed in cells that lack functional APC (Hart et al. 1998) . This indicates that Axin can also function downstream from, or independently of, APC, at least when overexpressed. From crystal structure studies, it was proposed that upon phosphorylation by GSK3 in the degradation complex, the affinity of APC for b-catenin increases and allows APC to compete with Axin for binding to b-catenin. In doing so, APC causes the release of b-catenin from Axin. Next, PP2A dephosphorylates APC such that phosphorylated b-catenin is freed from APC, and the destruction complex is made available for another b-catenin molecule to be targeted for degradation (Xing et al. 2003) .
Xenopus embryo injection assays using a form of Axin lacking the RGS domain (Axin-DRGS) showed that it behaves in a dominant-negative fashion and stabilizes b-catenin instead of degrading it (Zeng et al. 1997; Itoh et al. 1998) . In another study, however, the RGS domain appeared to be dispensable, as a truncated form of Axin lacking this domain was capable of downregulating b-catenin in a cell culture assay (Hart et al. 1998) . To resolve this issue with an in vivo assay, we generated mice with an Axin-DRGS knockin allele (Axin DRGS ). The second domain we study consists of six amino acids (KVEKVD) at the extreme C terminus of Axin (hereafter called the C6 motif). This sequence is identical in mouse, rat, and human Axin, and differs by only one amino acid in chick (KVEKID) or frog (QVEKID). It was reported that overexpression of Axin in HEK 293T cells activates the c-Jun N-terminal kinase ( JNK) through domains distinct from those involved in Wnt signaling (Zhang et al. 1999) and that the C6 motif was one of the domains required for JNK activation (Rui et al. 2002) . The deletion of the C6 motif impaired the ability of Axin to activate JNK, without affecting its ability to homodimerize or to function in the Wnt/b-catenin pathway. In addition to its potential role in JNK activation, the C6 motif is critical for the interaction of Axin with SUMO1-conjugating E3 enzymes, and it includes two lysine residues that were the main sites for the SUMOylation of Axin when Axin was cotransfected with HA-tagged SUMO (Rui et al. 2002) . Because the importance of Axin for JNK activation during normal development was unclear, as was the role of C-terminal SUMOylation in the functions of Axin, we generated a mutant Axin allele (designated Axin DC6 ) lacking these six residues.
MATERIALS AND METHODS
Targeting vectors, ES cells, mice and embryonic fibroblasts: Two targeting vectors flanked by Axin homology arms, pMTAX DRGS and pMTAX
DC6
, were constructed for the generation of mutant alleles ( Figure 1B ), as described (Chia and Costantini 2005) . For the construction of pMTAX DRGS , myc-tagged AxinDRGS cDNA was excised from pCS2-MT 1 AxinDRGS using ClaI and NotI, the ends blunted, and cloned into the ClaI site of pBluescript IISK, as described for construction of the pMTAX targeting vector (Chia and Costantini 2005) . To create Myc-tagged AxinDC6 cDNA, two sets of PCR reactions were performed simultaneously using primers AXSPE (GCTATTCCGAGAACGCAGGCAC) and mutSUMO (CTGCCCAGTGCTCAGCCGATGATCTTTT CTTCAAAGACAGG) and SUMOend3 (TGAGCACTGGG CAGCACAC) and T3 (AATTAACCCTCACTAAAGGG) on pCS2-MT 1 Axin as a template. The products of the two PCR reactions were then annealed and used as templates for another round of PCR using primers AXSPE and T3. The final PCR product was cut with SpeI and SacII and subcloned into pCS2-MT 1 Axin that had also been digested with SpeI and SacII. This new vector is pCS2-MT 1 AxinDC6. To create the targeting vector pMTAX
, Myc-tagged Axin-DC6 cDNA was excised from pCS2-MT 1 AxinDC6 using ClaI and NotI, ends blunted, and cloned into the ClaI site of pBluescriptIISK, as described for construction of the pMTAX vector (Chia and Costantini 2005) .
The targeting vectors were linearized with NotI and electroporated into CSL3 ES cells (derived from strain 129/SvEv, a gift of Victor Lin), which were selected with 0.35 mg/ml G418. DNA from surviving colonies was digested with HpaI and screened by Southern blot using a 479-bp probe, PB (see Figure 1B ), generated by PCR of genomic DNA with primers 59-CTTCTAATGGTATGAGGCTG-39 and 59-GCATCTGCACT TGCCATCTAC-39 (Chia and Costantini 2005) . This probe is located outside the homology arms of the targeting vector, so the change in band size in mutant clones must reflect a recombination event that altered the structure of the endogenous Axin locus. By the criteria of Southern blotting, correctly targeted clones were isolated for both alleles ( Figure  1C) , with targeting frequencies of 9/300 and 8/300 for pMTAX DRGS and pMTAX
, respectively. Two Axin DRGS ES clones (R1 and R24) and two Axin DC6 ES clones (S58 and S191) were injected into C57BL/6J (B6) blastocysts. Highly chimeric males made with clones R1, R24, and S58 were mated to B6 females to obtain initial germline transmission, and to b-actin-Cre transgenic females (Lewandoski 2001) to obtain progeny in which the PGKneo cassette was removed ( Figure 1B ). Mice and embryos were genotyped by PCR ( Figure 1D ) using the following primers: AXL1 (59-GGACCACCTTTCCTAATCCTTG-39) and MTAXR1 (59-AACCCTGCTCCTGGACATTC-39), which amplify the wild type (146 bp) and the AX AX , AX DRGS , and AX DC6 (404 bp) alleles, at annealing temperature 56.5°. To generate a null allele of Ctnnb1, we crossed a floxed allele (Brault et al. 2001 ) to a germ-line Cre strain (Lewandoski and Martin 1997) .
Mouse embryonic fibroblasts (MEFs) were prepared from E13.5 embryos of various genotypes and cultured in Dulbecco's modified Eagle's medium (DMEM, Sigma) supplemented with 10% heat-inactivated fetal bovine serum (FBS, HyClone Laboratories) and 50 mg/ml penicillin and streptomycin (GIBCO) in 5% CO 2 at 37°.
RT-PCR: Total RNA was prepared from MEFs using TRIzol (Ambion) and used for RT-PCR with a pair of primers specific for Axin, AXL2 (59-GAGATTGATTCCCTTGGGAGC-39) and MTAXR1 (59-AACCCTGCTCCTGGACATTC-39) (Chia and Costantini 2005) . The reactions were run at 94°(1 min), 65°(40 sec), and 72°(1 min) for 30 cycles.
Western blots: Embryos were dissected at E10.5 and homogenized as described (Fagotto et al. 1999) . Protein lysates were prepared from MEFs using RIPA buffer as described (Kim et al. 2008) . The anti-Axin polyclonal antibody (against full-length mouse Axin) was from David Virshup and used at a dilution of 1/20,000.
JNK assays: MEFs from wild type, Axin
DC6/DC6
;Ctnnb11/À, or Ctnnb11/À E13.5 embryos were cultured in DMEM, UV irradiated (100 mJ/m 2 ) and lysed with nondenaturing cell lysis buffer (Cell Signaling no. 9803) plus 1 mm PMSF after incubation for 0, 0.5, 1, or 2 hr. JNK assays were conducted with PathScan Phospho SAPK/JNK (Thr183/Tyr185) Sandwich ELISA kit and Total SAPK/JNK Sandwich ELISA kit (Cell Signaling).
Xenopus embryo experiments: Micro-injections of RNAs into Xenopus laevis embryos were carried out as described (Itoh et al. 1998) . RNAs for micro-injection were transcribed in vitro from pCS2-MT 1 Axin and pCS2-MT 1 AxinD6 linearized with SacII using mMessage mMachine SP6 kit (Ambion). To monitor ventralizing activities of Axin constructs, RNAs at the dose of 0.7 or 2 ng were injected into two dorsovegetal blastomeres of 4-8 cell embryos. Injected embryos were scored according to dorsoanterior index (DAI) (Kao and Elinson 1988) when uninjected control embryos reached stage 36. DAI 5 is scored as normal; DAI 4, reduced eyes and forehead; DAI 3, cyclopic; DAI 2, microcephalic; DAI 1, acephalic, and DAI 0, no dorsal axial structures. Two experiments were performed with essentially the same results. To assess protein expression levels, Western blot analysis of embryo lysates was carried out with anti-Myc antibodies as described (Itoh et al. 1998) , when uninjected sibling embryos reached early gastrula stage.
DNA Sequencing: Two primers flanking the C-terminal region of Axin cDNA (pDIX: CACCATGTGACAGCATTG and DIXp: TGTCCACCTGACTGATGAC) were used for PCR amplification of genomic DNA from Axin Ax/1 and Axin DC6/1 mouse tails. The products were subcloned and sequenced. Primers pDIX and DIXp are located in different exons and therefore the PCR product is only amplified from knockin cDNA and not endogenous Axin.
RESULTS

Generation of
Axin DRGS and Axin DC6 mutant alleles: The targeting strategy ( Figure 1B and materials and methods) was similar to that previously used to replace the Axin gene with wild-type Axin or Axin2 cDNAs, including a Myc-tag at the N terminus (Chia and Costantini 2005) . Correctly targeted ES cell clones were identified by Southern blotting ( Figure 1C and data not shown), and transmission of the wild-type and mutant alleles was detected by PCR ( Figure 1D ). Although the neo cassette had no apparent effect on Axin expression levels or on the mutant phenotypes, it was removed by crossing mice carrying the targeted Axin alleles to a b-actin/Cre recombinase transgenic line (Lewandoski and Martin 1997) .
To determine the level of expression of the Axin
DC6
and Axin DRGS alleles, protein extracts from heterozygous embryos (in which the endogenous Axin serves as an internal control) were analyzed by Western blotting with anti-Axin antibodies. Mouse embryos heterozygous for the Axin Ax allele (which contains a wild-type, Myc-tagged Axin cDNA inserted at the Axin locus) expressed levels of Myc-tagged Axin (which is $20 kDa larger due to the addition of six Myc epitopes) approximately equal to, or slightly higher than, endogenous Axin ( Figure 1E , lane 3). Therefore, the presence of the Myc tag, or the use of a cDNA sequence to encode Axin, does not reduce the level of expression compared to that encoded by the normal allele, as reported previously (Chia and Costantini 2005) . However, we found that the level of the Axin-DC6 protein was three-to fourfold lower than the endogenous Axin in heterozygous Axin DC6/1 embryos ( Figure 1E , lanes 4 and 5) or Axin DC6/1 MEFs (Figure 1F , lane 2). In contrast, the level of Axin-DC6 mRNA was equivalent to that of endogenous Axin mRNA, as shown by RT-PCR ( Figure 1G ), suggesting that the Axin-DC6 protein was either inefficiently translated or less stable than wild-type Myc-tagged Axin. While the presence of a six-amino-acid deletion at the C terminus is unlikely to affect translational efficiency, Axin-DC6 protein was found to have a reduced half-life (Kim et al. 2008) , which largely accounts for its reduced steadystate level. Surprisingly, Axin-DC6 protein was below the limit of detection in Axin DC6/DC6 MEFs (derived from homozygous Axin DC6/DC6 embryos ''rescued'' by removal of one Ctnnb1 allele; see below) ( Figure 1F, lane 3) . This suggests that in Axin DC6/1 heterozygotes, Axin-DC6 may be partially stabilized by dimerization with wild-type Axin.
The deletion of the RGS domain compensates in size for the addition of the Myc tags, so that the Myc-tagged Axin-DRGS protein comigrates with untagged wild-type Axin on SDS-polyacrylamide gels ( Figure 1H , lane 6). Therefore, we examined the level of Myc-Axin-DRGS protein in compound heterozygotes with the Axin Ax allele ( Figure 1H , lanes 4 and 5). This showed that Myc-Axin-DRGS is present in embryos at a level only slightly lower than wild-type Myc-Axin (average 80%). Thus, unlike the C6 deletion, removal of the RGS domain does not significantly affect the steady-state level of the mutant Axin protein.
Embryonic recessive lethality of the Axin DRGS allele: Although the dominant-negative activity of Axin-DRGS in frog embryo and cell culture assays suggested that it might cause dominant defects in mutant mice (Zeng et al. 1997; Fagotto et al. 1999) , Axin DRGS/1 heterozygous mice did not display visible abnormalities. Axin DRGS/1 mice were normally fertile, and backcrosses to wild-type mice generated heterozygous offspring at the expected frequency. However, in homozygotes, the Axin DRGS allele caused recessive embryonic defects very similar to those caused by a null allele, Axin Tg1 (Perry et al. 1995; Zeng et al. 1997) . Embryos from intercrosses among Axin DRGS/1 mice were examined at E9.5, and Axin DRGS/ DRGS homozygotes were found at the expected frequency (5/22), (Figure 2 , E-G) and indistinguishable from homozygotes for the null Axin Tg1 allele (Figure 2 , A-C). They were much smaller than wild-type or heterozygous littermates ( Figure 2D ) and displayed characteristic abnormalities also seen in null Axin Tg1/Tg1 embryos (Perry et al. 1995) , including a severely underdeveloped trunk, kinky neural tube, failure to turn, open and shortened head folds, enlarged pericardium, and cardia bifida.
Loss of the Axin C6 motif results in recessive embryonic lethality: Axin DC6/1 heterozygotes appeared normal, fertile, and transmitted the Axin DC6 allele at a frequency of $50%. However, Axin DC6/DC6 homozygous mice could not be generated. Of 22 F 2 pups obtained at weaning from Axin DC6/1 intercrosses, 12 were Axin DC6/1 while the remaining 10 were wild type. Since we had not noted any postnatal death, we concluded that Axin DC6 was likely to be prenatal recessive lethal allele. Axin DC6/DC6 embryos were examined at E9.5 to -10.5, stages at which the Axin Tg1/Tg1 null homozygotes were severely abnormal but not yet resorbed (Perry et al. 1995; Zeng et al. 1997 ). There were 32/137 mutant homozygotes, consistent with the expected 25% frequency, and all were severely abnormal (Figure 2, H-K (Perry et al. 1995; Zeng et al. 1997) . Therefore, we conclude that Axin DC6 also acts essentially as a null allele. The Axin-DC6 protein is fully active in the canonical Wnt pathway: The recessive lethality of the Axin DC6 allele could be due to inherent defects in mutant Axin-DC6 protein (in its ability either to regulate the canonical Wnt pathway or to carry out some other, unknown, function of Axin), or else they might be due simply to the low level of the mutant Axin protein. To try to distinguish between these explanations, we performed a number of experiments to analyze the properties of the Axin-DC6 protein. First, to rule out the trivial explanation that we had made the wrong mutation, we verified the presence of the expected targeted mutation at the Axin locus by sequencing a PCR product generated from genomic DNA prepared from Axin DC6/DC6 embryos (Figure 1I ). This confirmed that the mutation was as expected.
It was previously reported that deletion of the C6 motif does not impair the ability of Axin to attenuate LEF1 luciferase reporter activity, or to reduce the cellular b-catenin level when cotransfected with b-catenin (Rui et al. 2002) . We confirmed that Axin-DC6 is indistin- Figure 2. guishable from wild-type Axin in its ability to negatively regulate a LEF1 luciferase reporter when cotransfected into 293 cells along with b-catenin (data not shown).
To confirm in a different assay that the Axin-DC6 protein is fully functional in the canonical Wnt pathway, we examined its ability to ventralize Xenopus embryos when its mRNA was injected into the dorsal side of four cell-stage Xenopus embryos, an established assay for proteins that inhibit the Wnt pathway. The results indicated that the Axin-DC6 protein is capable of promoting b-catenin degradation. In fact, surprisingly, Axin-DC6 had stronger ventralizing effects than fulllength Axin, at two different dosages (Figure 3) . Thus, we conclude that the defects of Axin DC6/DC6 mutant embryos are not due to any inherent inability of this truncated protein to inhibit the canonical Wnt pathway when overexpressed.
The recessive embryonic lethality of the Axin DC6 allele is due to a failure to regulate the level of b-catenin in vivo: As a genetic test of its activity in the canonical Wnt/b-catenin pathway, we attempted to rescue the embryonic lethality of Axin DC6/DC6 mutants by making them heterozygous for a b-catenin null allele (Ctnnb1 1/À ), and thus reducing the level of b-catenin. If the lethality was due to failure of Axin DC6 to regulate the b-catenin level, resulting in its excessive accumulation, then reducing the Ctnnb1 gene dosage might compensate and thus partially correct the phenotypic defects. On the other hand, if the lethality were due to the effects of this Axin mutation on a different signaling pathway, then reducing the Ctnnb1 gene dosage should have no effect. Surprisingly, we found that removal of one allele of Ctnnb1 was able to completely rescue the embryonic lethality caused by the Axin DC6 allele. While Axin
DC6/DC6
embryos were all severely abnormal by E9.5 and resorbed by E11.5, Axin
; Ctnnb1 1/À compound mutants were able to develop to the end of gestation (E18.5, when they were sacrificed). We obtained two Axin DC6/DC6 ; Ctnnb1 1/À compound mutants at this stage, both of which had apparently normal bodies, while only the face and head were abnormal (Figure 4 , A and B, left). One had a mild cleft lip and a protruding tongue ( Figure 4A, left) , and the other had more severe facial clefting, with the brain protruding from the oral cavity above the tongue (Figures 4B, left) . Sectioning of the mutant embryo in Figure 4B (left) revealed multiple abnormalities, including cleft palate (arrows), absence of nasal structures (asterisk), and multiple brain malformations ( Figure 4C, left) .
To examine the developmental timing of the craniofacial abnormalities in these ''rescued'' Axin DC6/DC6 ; Ctnnb1 1/À mutants, additional embryos were examined at earlier prenatal stages. The facial defects could be traced back to E11.5, when impaired fusion of the medial nasal prominences was already visible (not shown). Figure 4D (left) shows an example of a rescued mutant at E14.5, in which the facial prominences failed to fuse. These defects were never seen in any other genotypic combination, nor were Axin DC6/DC6 embryos not carrying the Ctnnb1 mutant allele found at E11.5 or later.
In conclusion, the ability to rescue the pre-E10.5 embryonic lethality of the Axin DC6/DC6 mutant embryos by reducing the Ctnnb1 gene dosage strongly suggests that the early lethality of the Axin DC6/DC6 mutants is due to a deficiency in regulating the Wnt/b-catenin pathway. Thus, while the mutant protein is capable of regulating this pathway when overexpressed, it fails to do so in the homozygous mutant embryos, presumably because it is present at too low a level.
To ask if reduced JNK activity might contribute to the craniofacial defects of Axin DC6/DC6 ; Ctnnb1 1/À compound mutants, we performed JNK assays on UV-irradiated MEFs isolated from Axin DC6/DC6 ; Ctnnb1 1/À and control Figure 3 .-Ability of Axin-DC6 to inhibit axis formation in frog embryos. Injection of Axin-DC6 RNA into dorsal blastomeres of four-cell stage Xenopus embryos resulted in ventralization. Axin-DC6 and full-length Axin were tested at two different concentrations, and Axin-DC6 displayed a somewhat increased activity in this assay. DAI, dorsoanterior index: 5 is normal and 1 is the most strongly ventralized. E13.5 embryos, but saw no differences in JNK activity (data not shown). While this did not rule out a role for JNK activation by Axin, it failed to provide support for this hypothesis.
The Axin DC6 and Axin DRGS alleles fail to complement each other: Since Axin is believed to function as a dimer, it was possible that intragenic complementation between two different embryonic lethal alleles might partially or fully rescue embryonic development. If the reduced amount of Axin-DC6 protein were sufficient to support development, but the protein were functionally defective (i.e., if the last six amino acids were important for functions other than stability), it might be able to complement a different deletion allele, via dimerization between the two mutant proteins. To test this possibility, Axin DC6/1 and Axin DRGS/1 mice were crossed. No compound heterozygotes were found among 30 live-born progeny, nor among 30 conceptuses recovered at E12.5. At E12.5, none of the 20 live embryos were compound heterozygotes, and there were 10 empty decidua (whose contents could not be genotyped), suggesting that the compound mutant embryos had already been resorbed. At E9.5, 7/29 embryos were Axin DC6/DRGS compound heterozygotes, and all were developmentally delayed and phenotypically similar to homozygotes for the Axin Tg1 , Axin
DC6
, or Axin DRGS alleles (Figure 2 , L, M, and N). Thus, Axin DC6/DRGS compound heterozygotes die at the same stage as homozygotes for either mutation. While the failure to complement does not exclude a functional defect in the Axin-DC6 protein, it is consistent with the interpretation that embryonic lethality is due to the low level of Axin-DC6 protein.
DISCUSSION
In this study, we used targeted gene replacement in mice to investigate the in vivo significance of two conserved domains of Axin, the APC-binding (RGS) domain and the terminal C6 motif (KVEKVD). While this strategy is more laborious than many other experimental approaches, it has the advantage that it preserves the normal pattern and level of transcription of the endogenous locus, while also knocking out the endogenous gene. Therefore, mutant forms of the protein are assayed for their functions in vivo, and in the absence of the endogenous gene product. We found that the RGS domain and the C6 motif are both required for the normal activity of Axin, as homozygotes for either deletion allele displayed embryonic lethality and abnormalities indistinguishable from those caused by a null allele. However, the mechanisms by which they disrupt the function of Axin appear to be different.
The RGS domain is required for binding to APC in vitro, but there were conflicting data regarding its importance for the function of Axin in the canonical Wnt pathway (Zeng et al. 1997; Hart et al. 1998; Ikeda et al. 1998) . Our finding that Axin DRGS/DRGS mutants resemble null Axin Tg1/Tg1 embryos at E9.5 confirms that the RGS domain is required for the functions of Axin in vivo, presumably because it is needed to interact with APC (although other potential functions of the RGS domain cannot be excluded). Although Axin lacking its RGS domain acts as a dominant-negative in frog embryo and cell transfection assays (Zeng et al. 1997; Fagotto et al. 1999 ), we did not observe any abnormalities in heterozygous Axin DRGS/1 animals. This may be because the amount of the mutant protein in heterozygous mice is lower than it is in typical overexpression experiments, and it is therefore insufficient to inhibit the endogenous wild-type Axin.
Our interest in the C6 motif of Axin stemmed from a report that overexpression of Axin in HEK293 cells could activate the JNK MAP kinase through the upstream kinases MEKK1 and MEKK4 (Zhang et al. 1999 (Zhang et al. , 2000 (Zhang et al. , 2001 Rui et al. 2002) . Deletion analysis revealed that the two domains required for JNK activation are different from those needed for Wnt regulation. They included a region needed for Axin homodimerization (between residues 507 and 832) as well as the C6 motif. Thus, deletion of only C6 severely reduced the ability of Axin to activate JNK, but not to regulate b-catenin levels, in transfected cells. It was also shown that C6 is a major site for SUMOylation of Axin (Rui et al. 2002) , a modification whose significance remains unclear, although we have obtained evidence that SUMOylation of the C6 motif may protect Axin from ubiquitination (Kim et al. 2008) . We found that the Axin DC6 allele was also recessive lethal, and that Axin DC6/DC6 embryos died at the same stage as null Axin Tg1/Tg1 mutants, with the same spectrum of defects. However, this embryonic lethality appears most likely to be due to a low level of expression of the Axin-DC6 protein, rather than to any inherent functional defect in the mutant protein, for the following reasons.
First, in heterozygous embryos, where the level of Axin-DC6 protein should have been equivalent to wildtype Axin, it was present at three-to fourfold lower levels, while in homozygous mutant embryos it was undetectable (probably ,10% of wild-type levels). Subsequent biochemical experiments have shown that the removal of the C6 motif results in increased ubiquitination and decreased stability of Axin-DC6, apparently due to the loss of the SUMOylation sites within the C6 motif (Kim et al. 2008) .
Second, Axin-DC6 showed a normal capacity to attenuate a Lef1-luciferase reporter in transfected cells, and a somewhat enhanced ability to ventralize frog embryos when injected dorsally at the four-cell stage. Both of these assays may be relatively insensitive to the stability of the protein; however, they have been used extensively to define functional domains of Axin, and other proteins involved in canonical Wnt signaling, so any inherent defect in the ability of Axin-DC6 to regulate this pathway probably would have been apparent in these experiments.
Third, the embryonic lethality of Axin DC6/DC6 mutants could be rescued by eliminating one allele of the b-catenin gene Ctnnb1, and these rescued mutants developed to term with craniofacial defects, but no other gross abnormalities. This provided genetic proof that the early lethality and multiple abnormalities at E9.5-E10.5 are due to failure of the Axin DC6 allele to negatively regulate the level of b-catenin. Further evidence that the embryonic lethality of both Axin Tg1/Tg1
and Axin DC6/DC6 mutants can be explained by failure to regulate the Wnt/b-catenin pathway comes from the observation that overexpression of cWnt8c in the mouse embryo resulted in a very similar embryonic lethal phenotype (Pö pperl et al. 1997) . Since the Axin-DC6 protein is capable of regulating b-catenin levels when overexpressed but fails to do so in homozygous mutant embryos, the simplest explanation is its low level of expression.
Although the embryonic lethality of Axin DC6/DC6 mutants was rescued by reducing the level of b-catenin, the rescued animals displayed severe craniofacial abnormalities. These residual defects in craniofacial development could be due either to incomplete rescue of the excessive b-catenin signaling or to a failure of Axin DC6 to perform a different function.
According to the first model, strongly elevated levels of b-catenin cause the embryonic lethal phenotype, while mildly elevated levels cause only craniofacial defects. Evidence consistent with this model comes from analysis of compound mutant mice between Axin and Axin2. While homozygous Axin2À/À mice develop normally except for skull malformations (caused by premature fusion of cranial sutures) ( Yu et al. 2005) , Axin2À/À embryos that were also missing one Axin allele were born with severe craniofacial abnormalities reminiscent of those seen in the rescued Axin DC6/DC6 ; Ctnnb1 1/À mutants. Furthermore, the defects in Axin2À/À; Axin1/À mice could be fully rescued by deletion of one allele of Ctnnb1 (B. Jerchow and W. Birchmeier, personal communication). Therefore, the evidence suggests that there may be a continuum of defects, ranging from embryonic lethality, to survival with craniofacial defects, to normal development, depending on the level of depletion of Axin and/or Axin2 and the consequent deregulation of b-catenin. This might be directly tested in the future by manipulating the levels of b-catenin in developing embryos. The ability of the Axin DC6/DC6 mutants to be rescued by reduction in b-catenin gene dosage was sensitive to genetic background (data not shown), suggesting that other genes that vary between inbred strains of mice may also affect the level of b-catenin signaling.
According to the second model, Axin might be important not only to negatively regulate b-catenin, but also, later in development, to perform another function. One such function might be related to its capacity to stimulate the JNK pathway via the C6 motif (Rui et al. 2002) . If this were true, one might expect knockout of JNK genes to result in defects similar to those caused by Axin
DC6
. Of the three JNK genes, Mapk8 ( JNK1) and Mapk9 (JNK2) are ubiquitously expressed while Mapk10 (JNK3) is expressed in the CNS (Kuan et al. 1999; Weston and Davis 2002) . Single knockouts of Mapk8, Mapk9, or Mapk10 cause only minor defects, none affecting craniofacial development ( Yang et al. 1997; Kuan et al. 1999; Sabapathy et al. 1999; Weston and Davis 2002) . Simultaneous loss of Mapk8 and J Mapk9 NK2 results in exencephaly and neural tube closure defects due to reduced apoptosis in the hindbrain (Kuan et al. 1999) , while Mapk8/Mapk10 and Mapk9/Map10 double mutants are viable ( Yang et al. 1997; Kuan et al. 1999) . However, the triple mutant has not been reported, so a role in craniofacial development has not been fully excluded.
It has recently been shown that JNK signaling in early Xenopus embryos can antagonize the canonical Wnt pathway, apparently by regulating the nucleocytoplasmic transport of b-catenin (Liao et al. 2006) . Therefore, any potential effects of Axin on JNK signaling may not be completely separable from its effects on b-catenin. Furthermore, Axin can interact with proteins involved in several signaling pathways (e.g., TGF-b), so we cannot exclude the additional possibility that the incomplete rescue of Axin DC6/DC6 by the b-catenin heterozygous deletion reflects a role for Axin in some other pathway. Regardless of the mechanism, the Axin-DC6 mutation establishes that the C6 motif has an essential function in vivo. This may be related to its ability to protect Axin from ubiquitination and instability (Kim et al. 2008) .
